title: Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS).
abstract: A number of common disorders of the peripheral nervous system are closely linked to a monoclonal gammopathy. In a minority of patients, the neuropathy represents the sentinel feature of a malignant plasma cell dyscrasia, such as multiple myeloma or its osteosclerotic variant, Waldenstrom's disease, amyloidosis, cryoglobulinemia or lymphoma; the vast majority have so-called "monoclonal gammopathy of undetermined significance" (MGUS). Sensory symptoms predominate with paresthesias, numbness, imbalance, and gait ataxia. Electrodiagnostic studies show mixed demyelinating and axonal features and often may be indistinguishable from findings in chronic inflammatory demyelinating polyneuropathy. Some have a pure axonal polyneuropathy, and in these patients the relationship to the paraprotein is less certain. With limited success, correlations have been made between the immunoglobulin type (IgM, IgG, or IgA) and the clinical and electromyographic characteristics of the neuropathy. The treatment of MGUS neuropathies poses a considerable challenge. Patients with IgG/IgA-MGUS have improved with corticosteroids or intravenous immune globulin. Only the benefit of plasma exchange has been substantiated in a controlled trial. The IgM neuropathies tend to be more refractory but often improve with similar regimens, particularly if cytotoxic agents are added in doses sufficient to reduce the amount of the M-protein. In addition to plasma exchange, chlorambucil, and cyclophosphamide, interferon-alpha is a novel therapy that holds promise for patients with IgM neuropathies associated with anti-myelin associated antibodies.
authors.affiliation: Neurology Service, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA. KGORSON@aol.com
authors.forename: K C
authors.initials: KC
authors.lastname: Gorson
mesh_terms: D000918:Antibody Specificity; D005069:Evaluation Studies as Topic; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D009185:Myelin Proteins / Q000276:immunology; D010265:Paraproteinemias / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D011115:Polyneuropathies / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*
chemical_list: D006023:Glycoproteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009185:Myelin Proteins